BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-594@pharmaconomics
DTSTAMP:20260707T040923Z
DTSTART;VALUE=DATE:20260131
DTEND;VALUE=DATE:20260201
SUMMARY:ZBIO Phase 3 — obexelimab (estimated date)
DESCRIPTION:Phase 3 trial results for obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) are due ~ Jan 31\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1953926/000110465926027961/tm268878d1_ex99-1.htm\n\nTrack it: https://www.pharmaconomics.com/e/594
URL:https://www.pharmaconomics.com/e/594
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:ZBIO catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR